The use of highly active antiretroviral therapy for the prevention of mother-to-child transmission of the human immunodeficiency virus in Nigeria

Journal of Obstetrics and Gynaecology

Volumn 30, Issue 4, 2010, Pages 362-366

  Chama, C M ^a   Bello, M ^a   Ajayi, B A ^a   Zarma, S ^a   Gashau, W ^a  

^a UNIVERSITY OF MAIDUGURI   (Nigeria)

Author keywords

HAART; HIV; PMTCT; Pregnancy; Transmission

Indexed keywords

EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; INDINAVIR; LAMIVUDINE; NEVIRAPINE; RITONAVIR; STAVUDINE; VIRUS DNA; ZIDOVUDINE;

ADOLESCENT; ADULT; ARTICLE; BLOOD CELL COUNT; CD4 LYMPHOCYTE COUNT; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; NIGERIA; OUTCOME ASSESSMENT; PATIENT COUNSELING; POLYMERASE CHAIN REACTION; PRENATAL CARE; PRIORITY JOURNAL; PUERPERIUM; SINGLE DRUG DOSE; TEACHING HOSPITAL; VERTICAL TRANSMISSION;

ADOLESCENT; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV INFECTIONS; HUMANS; INFANT, NEWBORN; INFANT, NEWBORN, DISEASES; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MALE; NIGERIA; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; YOUNG ADULT;

EID: 77952261309     PISSN: 01443615     EISSN: 13646893     Source Type: Journal    
DOI: 10.3109/01443611003672104     Document Type: Article

References (34)

1. Blattner W, Cooper E, Charurat M, Thompson B, Hanson C, Mofenson L, et al. 2000. Effectiveness of potent antiretroviral therapies in reducing perinatal transmission of HIV-1. Abstract LbOr 4. XII International AIDS conference, Durban, South Africa.
2. Catherine MW, Mary GF. 2007. Balancing maternal and infant benefits and the consequences of breast-feeding in the developing world during the era of HIV infection. Journal of Infectious Diseases 195:165-167.
3. Didier KE, Patrick AC, Renaud B, Besigin TG, Appolinaire H. 2008. Antiretroviral treatment in pregnant women with advanced HIV disease and pregnancy outcomes in Abidjan, Cote d'Ivoire. AIDS 22:1815-1820.
4. FMOH. 2008a. National seroprevalence survey of HIV among antenatal attendees. Abuja, Nigeria: National AIDS and STD control programme.
5. FMOH. 2008b. Update on PMTCT programme coverage. Abuja, Nigeria: National AIDS and STD control programme.
6. FMOH. 2007. National guidelines for the prevention of motherto-child transmission of HIV. Abuja, Nigeria: National AIDS and STD control programme.
7. FMOH. 2004. HIV seroprevalence survey. Abuja, Nigeria: National AIDS and STD control programme.
8. FMOH. 2002. Formative research on the knowledge, attitude and perceptions of HIV among pregnant women in Nigeria. Abuja, Nigeria: National AIDS and STD control programme.
9. Gray G, McIntyre J. 2007. HIV and pregnancy. British Medical Journal 334:950-953.
10. Helfgott AW, Erickson N, Lewis S, Doyle M, Pearson D, Bundrick C. 2000. Highly active antiretroviral therapy for the prevention of perinatal HIV. Miami, Florida: Society for Maternal-Fetal Medicine Annual Meeting. Abstract 289.
11. Ian S, Herve M, John H, John AB, Michael ML. 2005. Severe hepatotoxicity associated with nevirapine use in HIV infected subjects. Journal of Infectious Diseases 191:825-829.
12. John GB, Joel EG. 2007. Recommendations for antiretroviral therapy in pregnancy. In: Medical management of HIV infection. Johns Hopkins University School of Medicine. pp 116-126.
13. June MM, Charles LB, Marc HS, Virginia D, Kevin LC. 2009. Hepatotoxicity associated with long-versus shortcourse HIV-prophylactic nevirapine use. Drug Safety 32:147-158.
14. Jonathan L, Peter P, Stephen S, Douglas M, Ralf H. 2005. Appropriate use of nevirapine for long term therapy. Journal of Infectious Diseases 192:545-546.
15. Lockman S, Shapiro RL, Smeaton LM, Wester C, Thior I. 2007. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. New England Journal of Medicine 356:135-138.
16. MacCarthy S, Laher F, Nduna M, Farlane L, Kaida A. 2009. Responding to her question: a review of the influence of pregnancy on HIV disease progression in the context of expanded access to HAART in sub-Saharan Africa. AIDS Behaviour 13:566-571.
17. Phanuphak N, Apornpong T, Teeratakulpisarn S, Chaithorngwongwathana S, Taweeppolcharoen C. 2007. Nevirapineassociated toxicity in HIV-infected Thai men and women, including pregnant women. HIV Medicine 8:357-366.
18. Samelson R, Shapiro D, Touamala E. 2000. HIV vertical transmission rates according to antiretroviral therapy and viral load during pregnancy among 347 mother-child pairs. (PACTG 367). Miami Beach, Florida: Society for Maternal-Fetal Medicine Annual Meeting. Abstract 276.
19. SMART Study Group. 2008. Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial. Annals of Internal Medicine 149:289-299.
20. Tai JH, Udoji MA, Barkanic G, Byrne DW, Rebeiro PF. 2007. Pregnancy and HIV disease progression during the era of HAART. Journal of Infectious Diseases 196:1044-1052.
21. Tlale J. 2008. Maternal HAART reduces transmission of HIV through breast-feeding. Los Angeles, CA: IAS Conference Abstract COS 109.
22. Townsend CL, Cortina-Borja M, Peckan CS, Tookey PA. 2007. Antiretroviral therapy and premature delivery in diagnosed HIV-infected women in the United Kingdom and Ireland. AIDS 21:1019-1026.
23. Tuomala RE, Watts DH, Li D, Vajaranant M, Pitt J. 2005. Improved obstetric outcome and few maternal toxicities are associated with antiretroviral treatment including HAART during pregnancy. Acquired Immune Deficiency Syndrome 38:449-473.
24. UNAIDS. 2008. Report on the global AIDS epidemic 2008. Available at: www.unaids.org/en/knowledgecentre/HIV-data/globalreport2008 (Accessed 10 September 2009).
25. van Benthem BH, Vernazza P, Coutinho RA, Prins M. 2002. European study on the natural history of HIV in women and the Swiss HIV cohort study: the impact of pregnancy and menopause on CD4 lymphocyte counts in HIV infected women. AIDS 16:919-924.
26. Watts DH. 2008. 12th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA: Abstract S 109.
27. WHO. 2004. The global burden of disease 2004 update. Available at: www.who.int/healthinfo/global-burden-disease (Accessed 1 February 2009).
28. WHO. 2007. HIV and infant feeding: new evidence and programmatic experience: report of a technical consultation held on behalf of the inter-agency task team (IATT) on prevention of HIV infection in pregnant women, mothers and their infants, 2006. Available at: http//whqlibdoc.who.int/ publications/2007 (Accessed 10 September 2009).
29. Di Spiezio Sardo A, Mazzon I, Gargano V et al. 2008. Hysteroscopic treatment of atypical polypoid adenomyoma diagnosed incidentally in a young infertile woman. Fertility and Sterility 89:456e9-456e12.
30. Heatley MK. 2006. Atypical polypoid adenomyoma: a systemic review of the English literature. Histopathology 48:609-610.
31. Longacre TA, Chung H, Rouse RV et al. 1996. Atypical polypoidadenomyofibromas (atypical polypoid adenomyomas) of the uterus: a clinicopathologic study of 55 cases. American Journal of Surgical Pathology 20:1-20.
32. NICE. 2007. Heavy menstrual bleeding. Clinical Guideline 44. National Institute for Health and Clinical Excellence, London. Available at: www.nice.org.uk/nicemedia/pdf/CG44FullGuideline. pdf (Accessed 8 February 2010).
33. Sugiyama T, Ohta S, Nishida T et al. 1998. Two cases of endometrial adenocarcinoma arising from atypical polypoid adenomyoma. Gynecologic Oncology 71:141-144. (Pubitemid 28492410)
34. Tashiro H, Katabuchi H, Fukumatsu Y et al. 1998. Endometrial adenocarcinoma following the conservative treatment of an atypical polypoid adenomyoma. International Journal of Clinical Oncology 3:400-402.